|
US2006084073A1
|
|
Nucleic acids encoding human TBC-1 protein and polymorphic markers thereof
|
|
AU2003232404A1
|
|
Homotrimeric extended obg3 globular head and uses thereof
|
|
AU2003223070A1
|
|
Obg3 fragments inhibiting the conversion of active obg3 into less active obg3 and other compositions for treatment of metabolic disorders
|
|
WO03095485A2
|
|
Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders
|
|
WO03082915A2
|
|
Xcrf polynucleotides and polypeptides and uses thereof
|
|
AU2003219167A1
|
|
Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists
|
|
EP1453854A2
|
|
Human cdnas and proteins and uses thereof
|
|
US2004067881A1
|
|
OBG3 globular head and uses thereof
|
|
WO03050303A2
|
|
Biallelic markers of d-amino acid oxidase and uses thereof
|
|
AU2002339696A1
|
|
Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
|
|
AU2002339699A1
|
|
Use of obg3 for promoting central nervous system remyelination
|
|
WO03051911A2
|
|
Gmg-5 polynucleotides and polypeptides and uses thereof
|
|
WO03049757A1
|
|
Agonists and antagonists of glucomin for the treatment of metabolic disorders
|
|
AU2002339680A1
|
|
Agonists and antagonists of bromix for the treatment of metabolic disorders
|
|
WO03047614A1
|
|
Agonist and antagonists of redax for the treatment of metabolic disorders
|
|
WO03049759A1
|
|
Agonists and antagonists of oxifan for the treatment of metabolic disorders
|
|
AU2002339691A1
|
|
Agonists and antagonists of prolixin for the treatment of metabolic disorders
|
|
WO03047615A1
|
|
Dexar agonists and antagonists for use in the treatment of metabolic disorders
|
|
AU2002339688A1
|
|
Glucoset agonists and antagonists for use in the treatment of metabolic disorders
|
|
AU2002339682A1
|
|
Emergen agonists and antagonists for use in the treatment of metabolic disorders
|
